Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL

Martin, P; Bartlett, NL; Chavez, JC; Reagan, JL; Smith, SM; LaCasce, AS; Jones, J; Drew, J; Wu, CQ; Mulvey, E; Revuelta, MV; Cerchietti, L; Leonard, JP

Martin, P (通讯作者)，Weill Cornell Med Coll, New York, NY 10021 USA.

BLOOD, 2022; 139 (8): 1147

Abstract

Resistance to standard immunochemotherapy remains an unmet challenge in diffuse large B-cell lymphoma (DLBCL), and aberrant DNA methylation may contri......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索